Biogen enrols first patient in CHARM trial for LHI
Biogen has enrolled the first patient in the CHARM trial, a Phase llll clinical study investigating BIIB093 (intravenous (IV) glibenclamide)…
Biogen has enrolled the first patient in the CHARM trial, a Phase llll clinical study investigating BIIB093 (intravenous (IV) glibenclamide)…